Intranasal oxytocin augments brief couples therapy for veteran PTSD, targeting symptoms and relationship quality.
Background
Posttraumatic stress disorder (PTSD) significantly impacts veterans and their intimate relationships, often leading to chronic distress for both individuals and couples. While Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) is an established treatment designed to simultaneously improve PTSD symptoms and relationship functioning, its effects on relationship satisfaction can be modest, particularly within veteran populations. Oxytocin, a crucial neurohormone, plays a key role in social bonding, empathy, and stress regulation, mechanisms highly relevant to trauma recovery and relationship dynamics. Augmenting bCBCT with intranasal oxytocin presents a promising strategy to enhance therapeutic efficacy, addressing the current gap in comprehensively improving both PTSD and relationship quality for affected veterans.
Study Design
This Phase 2 randomized, placebo-controlled trial (NCT04523922) is designed to evaluate the clinical and functional outcomes of bCBCT augmented with intranasal oxytocin (bCBCT + OT) versus bCBCT plus placebo (bCBCT + PL). The study aims to enroll 175 participants, focusing on veterans with PTSD and their partners. Primary endpoints include changes in PTSD symptom severity and relationship satisfaction. Investigators will also explore potential mechanisms of action, such as improvements in communication, empathy, and trust, to understand how oxytocin might enhance therapeutic benefits.
Why It Matters
If successful, this trial could establish intranasal oxytocin as a valuable pharmacological adjunct to couples therapy for veterans with PTSD. This could lead to significantly improved treatment protocols that not only reduce PTSD symptoms but also substantially enhance relationship quality, a critical factor for long-term well-being and recovery in this population. For clinicians, it offers a potential strategy to more effectively address the often-overlooked relational distress inherent in PTSD. For veterans and their partners, it promises a more holistic and integrated therapeutic approach, leveraging social bonding mechanisms to foster deeper healing and connection. The exploration of underlying mechanisms like communication and empathy could also inform future personalized interventions.
oxytocin
ptsd
veterans
couples therapy
randomized controlled trial
phase 2